Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Share Price Pass Below 200-Day Moving Average – Here’s What Happened

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT)’s stock price passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $31.25 and traded as low as $27.50. Lakefront Biotherapeutics American Depositary Shares shares last traded at $28.11, with a volume of 148,929 shares traded.

Wall Street Analyst Weigh In

A number of brokerages have commented on LKFT. Weiss Ratings reissued a “hold (c)” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a report on Tuesday, May 26th. Zacks Research lowered shares of Lakefront Biotherapeutics American Depositary Shares from a “hold” rating to a “strong sell” rating in a research note on Friday, May 8th. Wall Street Zen lowered shares of Lakefront Biotherapeutics American Depositary Shares from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. UBS Group reaffirmed a “market perform” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a research note on Tuesday, February 24th. Finally, Royal Bank Of Canada lifted their price objective on shares of Lakefront Biotherapeutics American Depositary Shares from $32.00 to $33.00 and gave the stock a “sector perform” rating in a research note on Tuesday, February 24th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $36.50.

Lakefront Biotherapeutics American Depositary Shares Trading Down 0.3%

The firm’s 50 day moving average is $28.33 and its two-hundred day moving average is $31.23. The firm has a market cap of $1.85 billion, a P/E ratio of -19.87 and a beta of 0.26.

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) last released its quarterly earnings data on Sunday, February 15th. The biotechnology company reported $13.92 earnings per share for the quarter. The firm had revenue of $1.06 billion for the quarter. Analysts predict that Lakefront Biotherapeutics American Depositary Shares will post -6.32 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of LKFT. Ameriprise Financial Inc. lifted its stake in Lakefront Biotherapeutics American Depositary Shares by 2,490.1% in the third quarter. Ameriprise Financial Inc. now owns 1,416,934 shares of the biotechnology company’s stock valued at $49,083,000 after buying an additional 1,362,229 shares in the last quarter. UBS Group AG lifted its stake in Lakefront Biotherapeutics American Depositary Shares by 128.4% in the fourth quarter. UBS Group AG now owns 349,444 shares of the biotechnology company’s stock valued at $11,427,000 after buying an additional 196,445 shares in the last quarter. Millennium Management LLC lifted its stake in Lakefront Biotherapeutics American Depositary Shares by 121.9% in the fourth quarter. Millennium Management LLC now owns 339,354 shares of the biotechnology company’s stock valued at $11,097,000 after buying an additional 186,452 shares in the last quarter. Jane Street Group LLC lifted its stake in Lakefront Biotherapeutics American Depositary Shares by 2,245.7% in the first quarter. Jane Street Group LLC now owns 110,783 shares of the biotechnology company’s stock valued at $2,783,000 after buying an additional 115,946 shares in the last quarter. Finally, Kotler Kevin bought a new position in Lakefront Biotherapeutics American Depositary Shares in the fourth quarter valued at approximately $2,943,000. Institutional investors own 32.46% of the company’s stock.

Lakefront Biotherapeutics American Depositary Shares Company Profile

Galapagos NV (NASDAQ:GLPG) is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company’s discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.

The company’s pipeline encompasses multiple programs across various stages of development.